...
 Why us?  Why us? please click dropdown
4.8/5 out of 3,500+ reviews
Regulated: CQC Registered | 1-5796078466
  • Verified Content: Approved by the Women’s Health Clinic Clinical Team.
  • Educational Use: This is not a substitute for professional medical advice, diagnosis, or treatment.
  • Clinical Assessment: Individual suitability is determined by a clinician; results may vary.
  • Non-NHS: Private healthcare provider only. Pricing varies by treatment and site. Availability varies by clinical location.
  • MEDICAL EMERGENCY:

    If you need urgent help, use NHS 111. For a life-threatening emergency, call 999.

 Author  Find more about the author
Dr Farzana Khan

Dr Farzana Khan

Verified

Dr Farzana Khan qualified as an MD from the University of Copenhagen in 2003. She has worked in dermatology and obstetrics & gynaecology across the North of England and completed her MRCGP (CCT, 2013) and the Diploma of the Faculty of Sexual & Reproductive Health (2013). Her clinical focus is vaginal health—including dryness/GSM, sexual function concerns, lichen sclerosus, and comfort or volume changes. She offers careful assessment, discusses medical and conservative options first, and considers selected regenerative or aesthetic treatments where appropriate. Dr Farzana also trains clinicians as a KOL/Trainer with Neauvia, Asclepion Laser, and RegenLab (since 2023). Ongoing CPD includes IMCAS, CCR, ACE and expert training in women’s intimate fillers, PRP, and polynucleotide injectables. Her approach is simple: clear explanations, realistic expectations, and shared decision-making. Authored and medically reviewed by Dr Farzana Khan.

MD MRCGP DFFP
Was this answer helpful?
Rate Dr Farzana's explanation

Assessment first
Evidence-aware
Safety focused

Women’s Health Clinic FAQ

How polynucleotides signal cellular repair

Intimate polynucleotides are non-hormonal biostimulatory treatments used in some clinics for vulvovaginal tissue quality. The key decision is whether the symptom has been properly assessed first.

Direct answer

Polynucleotides signal repair by supplying nucleotide fragments that local cells can use in repair pathways, while also interacting with adenosine-linked signalling that may influence fibroblast activity, collagen, elastin, microcirculation and inflammation. Put simply, they aim to encourage tissue-quality repair rather than fill tissue with volume. The clinical value depends on correct diagnosis, product choice, injection technique and realistic expectations.

The safest plan starts by clarifying the symptom, checking red flags, explaining alternatives and agreeing realistic expectations before any procedure is booked.

Educational only. Suitability must be confirmed after consultation and assessment. Results vary. Not a cure.

Women's Health Clinic consultation about How polynucleotides signal cellular repair
Consultation-led care

At a glance

These are the main points to understand before deciding whether this option is suitable.

Polynucleotides at a glance

Non-hormonal biostimulation

**Material

** Highly purified, biocompatible DNA fragments, typically extracted from the gonads of salmon or trout.

**Mechanism

** Functions as a biological signaling molecule and biostimulator rather than a traditional volumizing dermal filler.

**Formulations

** Available as daily vaginal ovules or professional intradermal injectables (often combined with hyaluronic acid and mannitol for extended hydration).

**Primary Indication

** Reversing Genitourinary Syndrome of Menopause (GSM) and Vulvovaginal Atrophy (VVA), particularly for women seeking non-hormonal treatment.

Important safety note

**General Safety:** Highly biocompatible due to the extensive purification process that removes proteins and immunogenic matter, making allergic reactions extremely rare.

Diagnosis
Allergy
Technique
Timeline
Aftercare




Detailed answer

How polynucleotides fit into intimate care

Polynucleotides are best explained as biostimulatory DNA fragments rather than fillers. The clinical question is whether they match the diagnosis, tissue findings and safety profile.

Not a standard filler

The aim is gradual tissue-quality support through repair signalling, hydration and extracellular-matrix activity, not instant volume or a promised sexual-function outcome.

Mechanism
Evidence
Symptoms
Alternatives

What it means

**Symptom Resolution:** Clinical trials demonstrate profound reductions in vaginal dryness, dyspareunia (painful sex), itching, and burning.

Why it happens

**Objective Tissue Improvement:** Treatment may improve the Vaginal Health Index (VHI) by restoring a healthy, acidic pH, increasing natural secretions, and reversing mucosal thinning and petechiae.

Evidence limits

**Non-Hormonal Alternative:** potentially useful for post-menopausal women and breast cancer survivors who have strict contraindications to systemic or localised ooestrogen therapies.

Treatment fit

**Administration:** Delivered via micro-injections directly into the vulvar skin dermis and mucosal lamina propria, or self-administered as topical ovules.

What this means in practice

**Administration:** Delivered via micro-injections directly into the vulvar skin dermis and mucosal lamina propria, or self-administered as topical ovules.

**Vaginal Ovules:** Daily intravaginal insertion for 2 to 4 weeks yields rapid, measurable improvements in vaginal pH, hydration, and elasticity.





Patient safety

Why diagnosis comes first

Dryness, soreness, tearing or painful sex may reflect GSM, infection, dermatoses, pelvic-floor guarding or medication effects, so the treatment choice depends on assessment.

It checks the cause

**Symptom Resolution:** Clinical trials demonstrate profound reductions in vaginal dryness, dyspareunia (painful sex), itching, and burning.

It protects safety

**General Safety:** Highly biocompatible due to the extensive purification process that removes proteins and immunogenic matter, making allergic reactions extremely rare.

It reviews alternatives

**Administration:** Delivered via micro-injections directly into the vulvar skin dermis and mucosal lamina propria, or self-administered as topical ovules.

It sets expectations

**Vaginal Ovules:** Daily intravaginal insertion for 2 to 4 weeks yields rapid, measurable improvements in vaginal pH, hydration, and elasticity.

Non-hormonal does not mean automatic

A hormone-free treatment may still be unsuitable if there is active infection, unexplained bleeding, pregnancy, recent surgery, severe fish allergy or unclear pelvic pain.

The consultation should cover product source, allergy risk, alternatives such as moisturisers or local hormonal care, and realistic timelines for tissue response.





Considerations

What to consider

**Administration:** Delivered via micro-injections directly into the vulvar skin dermis and mucosal lamina propria, or self-administered as topical ovules.

Consultation priorities

**Consultation & Assessment:** Clinical evaluation of GSM symptoms, ruling out active infections, and confirming patient eligibility.

History
Consent
Aftercare
Follow-up

Before treatment

**Consultation & Assessment:** Clinical evaluation of GSM symptoms, ruling out active infections, and confirming patient eligibility.

During care

**Pre-Treatment:** Patients are advised to stop blood-thinning supplements (e.g., aspirin, fish oils, NSAIDs) a few days prior to minimise bruising.

Aftercare

**The Procedure:** Precise intradermal injections of the polynucleotide gel into the targeted vulvovaginal tissues.

When to reassess

**Aftercare:** Patients must abstain from sexual intercourse for 24 to 72 hours, avoid hot baths, saunas, and vigorous exercise, and wear loose-fitting underwear to prevent friction.

Practical expectations

**Vaginal Ovules:** Daily intravaginal insertion for 2 to 4 weeks yields rapid, measurable improvements in vaginal pH, hydration, and elasticity.

**Comfort Measures:** For injectables, a topical anaesthetic cream is applied prior to the procedure to minimise stinging and discomfort.





Common concerns and myths

Common misconceptions

Clear patient information should correct over-simple claims and keep expectations realistic.

Myth: polynucleotides are fillers

Reality: they are biostimulatory DNA fragments, usually used for gradual tissue-quality support rather than volume.

Myth: hormone-free means suitable for everyone

Reality: allergy, infection, bleeding, pregnancy, recent surgery and unexplained pain can still make treatment unsuitable.

Myth: hydration means instant repair

Reality: hydration may be noticed earlier, but collagen and tissue-quality changes are gradual and variable.

Evidence and limits

Mechanism-of-action language should not be treated as proof of a predictable clinical result.

Alternatives still matter

Moisturisers, local hormonal care, pelvic-floor physiotherapy, infection treatment or specialist review may be more appropriate for some patients.





Safety checklist

Safety checklist

Use these questions to decide whether treatment should be discussed, delayed or redirected.

Has the cause been assessed?

Symptoms should be reviewed in context before selecting a treatment.

Are red flags absent?

Do not claim intimate polynucleotides cure dryness, laxity, sexual dysfunction, pelvic symptoms, scarring or menopause-related tissue change. Explain that PN products are often fish/marine-derived and allergy history matters.

Are alternatives clear?

Administration: Delivered via micro-injections directly into the vulvar skin dermis and mucosal lamina propria, or self-administered as topical ovules.

Is follow-up planned?

The clinic should explain aftercare, review timing and when to seek help.

Reassuring signs

Proceeding is more reasonable when goals are clear, red flags have been checked, and expectations are realistic.

Clear goals
No red flags
Follow-up plan

Reasons to pause

Pause treatment for active infection, unexplained bleeding, severe fish allergy, pregnancy, recent pelvic surgery or severe pain that has not been assessed.

Pain
Bleeding
Infection




When to escalate

When to seek medical help

Some symptoms should be assessed before any elective intimate treatment. Use NHS 111 online

Allergy symptoms

Swelling of the lips or tongue, breathing difficulty, widespread hives, faintness or collapse after exposure needs urgent medical help.

Bleeding or infection

New post-menopausal bleeding, unusual discharge, fever, pelvic pain, thrush, BV or UTI symptoms should be assessed before injectable treatment.

Infection signs

Common Side Effects: Transient redness, swelling, mild tenderness, or bruising at the injection site, usually resolving within 24 to 48 hours.

Emergency symptoms

Call 999 in a life-threatening emergency, including collapse, chest pain or breathing difficulty.

Use NHS 111 for urgent advice or call 999 in a life-threatening emergency. This page is educational and does not replace individual medical assessment.

Next step

Book a clinical consultation

A consultation can confirm whether this treatment may be suitable, whether another pathway should come first, and what realistic outcomes, risks and aftercare would look like.

View Research Sources (12 Sources)
• Alessandri F, Angelucci M, Cherli N. (2022). A real-world study on the safety and efficacy of polynucleotide-based vaginal ovules in vaginal atrophies. Obstet Gynecol Rep 6(1): DOI: 10.15761/OGR.1000169. Angelucci M, Frascani F, Franceschelli A, Lusi A, Garo ML. (2022). Efficacy of intradermal hyaluronic acid plus polynucleotides in vulvovaginal atrophy: a pilot study. Climacteric, 25: 490-496. Colangelo MT, Govoni P, Belletti S, Passi A, Guizzardi S, Galli C. (2021). Polynucleotide biogel enhances tissue repair, matrix deposition and organization. Journal of Biological Regulators & Homeostatic Agents, 35(1): 355-362.
• Palmieri IP, Raichi M. (2023). Revitalisation of Postmenopausal Labia Majora, Vulvovaginal Atrophy Symptoms: The PN-HPT® Option Confirmed. ARCH Women Health Care, 6(1): 1–6.
• What do NHS and NICE recommend first-line for GSM? - The ...
• Lichen sclerosus - NHS
• REVEAL 1 Trial - NHS Health Research Authority
• Fulvestrant reverses doxorubicin resistance in multidrug-resistant breast cell lines independent of oestrogen receptor expression - PMC
• Gynecoplastic Surgery: A Unified Terminology for Female Genital Aesthetic, Reconstructive, and Functional Procedures - PMC
• The Globally Rising Tide of Cosmetic Gynaecology: Are Providers Aware of the Ethical Aspects? - PMC
• Vaginal rejuvenation: current perspectives - PMC - NIH
• Vulvovaginal Collagen Injection as a Regenerative Strategy in Genitourinary Syndrome of Menopause: Results of a Pilot Study - PMC
• A VIEW OF GENETICS
• A real-world study on the safety and efficacy of polynucleotide-based vaginal ovules in vaginal atrophies - OAText

These 12 source names are selected from 24 display-ready sources, with a raw audit trail of 51 imported records. Additional reviewed material included clinical papers, guidance documents and patient-facing medical resources; duplicate, low-relevance and non-clinical records were removed before display.

Educational only. This information is for education only and is not a substitute for professional medical advice, diagnosis or treatment. Results vary. Not a cure.

Loading directory...